{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:25:45Z","timestamp":1791555945306,"version":"4.3.4"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Clin. Diabetes Healthc."],"abstract":"<jats:p>\n                    Glucocorticosteroids (GCs) are commonly used in the treatment of autoimmune, inflammatory and neoplastic diseases. Although clinically effective, they are associated with significant metabolic side effects, including increased insulin resistance, impaired function of pancreatic\n                    <jats:italic>\u03b2<\/jats:italic>\n                    -cells, and, finally, weight gain. These effects can result in steroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID), both of which increase the risk of complications such as infections and prolonged hospitalisation. Intensive insulin therapy remains the standard treatment for SID. However, emerging evidence suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may have therapeutic potential to counteract the metabolic effects of steroids. This review evaluates the efficacy and safety of GLP-1 RAs for the treatment of SIH and SID.\n                  <\/jats:p>","DOI":"10.3389\/fcdhc.2026.1772391","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:27:16Z","timestamp":1775795236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review"],"prefix":"10.3389","volume":"7","author":[{"given":"Aleksandra","family":"J\u0119drasek","sequence":"first","affiliation":[{"name":"Department of Diabetology and Internal Medicine, Medical University of Warsaw","place":["Warsaw, Poland"]},{"name":"Doctoral School, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Lisowska","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Internal Medicine, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Czupryniak","sequence":"additional","affiliation":[{"name":"Department of Diabetology and Internal Medicine, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S330253","article-title":"Management of glucocorticoid-induced hyperglycemia","volume":"23","author":"Shah","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102154","article-title":"A practical guide for the management of steroid induced hyperglycaemia in the hospital","volume":"10","author":"Aberer","year":"2021","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01628-0","article-title":"Medication-induced hyperglycemia and diabetes mellitus: A review of cur252 rent literature and practical management strategies","volume":"15","author":"Jain","year":"2024","journal-title":"Diabetes Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.11.009","article-title":"Oral corticosterone administration reduces insulitis but promotes insulin resistance and hyperglycemia in male nonobese diabetic mice","volume":"187","author":"Burke","year":"2017","journal-title":"Am J Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/s0026-0495(98)90184-6","article-title":"Dexamethasone inhibits insulin-stimulated recruitment of glut4 to the cell surface in rat skeletal muscle","volume":"47","author":"Weinstein","year":"1998","journal-title":"Metabolism"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119175","article-title":"Direct glucocorticoid inhibition of insulin secretion. an in vitro study of dexamethas on eeffects in mouse islets","volume":"99","author":"Lambillotte","year":"1997","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2024.1951","article-title":"Glucocorticoid-induced hyperglycemia: A neglected problem","volume":"39","author":"Choo","year":"2024","journal-title":"Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5603\/DK.2015.0010","article-title":"Glucocortycosteroids and disturbances of glucose metabolism","volume":"4","author":"Pisarczyk-Wiza","year":"2015","journal-title":"Clin Diabetol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13195801","article-title":"Is it time for a new algorithm for the pharmacotherapy of steroid-induced diabetes","volume":"13","author":"Ostrowska-Czy\u017cewska","year":"2024","journal-title":"J Clin Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2015.02.014","article-title":"Glucocorticoids decrease the production of glucagon-like peptide-1 at the transcriptional level in intestinal l-cells","volume":"406","author":"Sato","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2459-7","article-title":"Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes","volume":"55","author":"Jensen","year":"2012","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1998.275.5.e806","article-title":"Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans","volume":"275","author":"Schneiter","year":"1998"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2174-9","article-title":"Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial","volume":"54","author":"van Raalte","year":"2011","journal-title":"Diabetologia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16378","article-title":"Glucocorticoid-induced hyperglycaemia in hospitalised adults: A matched cohort study (2013-2023)","volume":"27","author":"Golubic","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S016","article-title":"16. diabetes care in the hospital: Standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/93.2.105","article-title":"Use of oral corticosteroids in the United Kingdom","volume":"93","author":"van Staa","year":"2000","journal-title":"QJM: Int J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S002","article-title":"2. diagnosis and classification of diabetes: Standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.14-3-326a","article-title":"How frequently are bedside glucose levels measured in hospital inpatients on glucocorticoid treatment","volume":"14","author":"Narwani","year":"2014","journal-title":"Clin Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000647","article-title":"Monitoring of patients on long-term glucocorticoid therapy","volume":"94","author":"Fardet","year":"2015","journal-title":"Medicine"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000365892","article-title":"Hyperglycemia induced by glucocorticoids in nondiabetic patients: A meta-analysis","volume":"65","author":"Liu","year":"2014","journal-title":"Ann Nutr Metab"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061476","article-title":"Metabolic adverse events associated with systemic corticosteroid therapy\u2014a systematic review and meta-analysis","volume":"12","author":"Kulkarni","year":"2022","journal-title":"BMJ Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221147937","article-title":"Continuous glucose monitoring of steroid-induced hyperglycemia in patients with dermatologic diseases","volume":"18","author":"Kleinhans","year":"2024","journal-title":"J Diabetes Sci Technol"},{"key":"B25","article-title":"Steroid-induced diabetes in rheumatologic patients","volume":"32","author":"Angelopoulos","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (rewind): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with glp-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (gip and glp-1) in metabolic and cardiovascular disease: A pathophysiological update","volume":"23","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1042\/CS20140719","article-title":"Glucocorticoids suppress glp-1 secretion: possible contribution to their diabetogenic effects","volume":"129","author":"Kappe","year":"2015","journal-title":"Clin Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1677","article-title":"Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans","volume":"34","author":"van Raalte","year":"2011","journal-title":"Diabetes Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14633","article-title":"Effectiveness and safety of glucagon-like peptide-1 receptor agonist in a cohort of kidney transplant recipients","volume":"36","author":"Vigara","year":"2022","journal-title":"Clin Transplant"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae018","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis","volume":"17","author":"Krisanapan","year":"2024","journal-title":"Clin Kidney J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.1953","article-title":"Evaluating the use of glucagon-like peptide-1 receptor agonists in a matched cohort of kidney and liver transplant recipients","volume":"55","author":"Baik","year":"2025","journal-title":"J Pharm Pract Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.36468\/pharmaceutical-sciences.spl.428","article-title":"Evaluation of the efficacies of liraglutide and glargine in type 2 diabetes patients with Malignant tumors treated with glucocorticoids","volume":"84","author":"Pu","year":"2022","journal-title":"Indian J Pharm Sci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12902-020-0542-5","article-title":"Dulaglutide improves glucocorticoid-induced hyperglycemia in inpatient care and reduces dose and injection frequency of insulin","volume":"20","author":"Uchinuma","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2169\/internalmedicine.52.8622","article-title":"Evaluation of the effects of exenatide administration in patients with type 2 diabetes with worsened glycemic control caused by glucocorticoid therapy","volume":"52","author":"Matsuo","year":"2013","journal-title":"Internal Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18999\/nagjms.83.2.343","article-title":"The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis","volume":"83","author":"Zhang","year":"2021","journal-title":"Nagoya J Med Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.14740\/jem491w","article-title":"Steroid-induced hyperglycemia successfully treated with once-weekly dulaglutide in an old patient with type 2 diabetes","volume":"8","author":"Hamasaki","year":"2018","journal-title":"J Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1028-P","article-title":"Is once-weekly glp-1 receptor agonist a reasonable option for glucocorticoid-induced hyperglycemia? twelve-week efficacy and safety of dulaglutide vs. sitagliptin in patients with diabetes on routine glucocorticoid treatment","volume":"68","author":"Yoshiji","year":"2019","journal-title":"Diabetes"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118163","article-title":"Unraveling the safety profile of glp-1 receptor agonists: Mechanistic insights with a focus on semaglutide","volume":"15","author":"He","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/jcpt.13225","article-title":"Safety and tolerability of once-weekly glp-1 receptor agonists in type 2 diabetes","volume":"45","author":"Trujillo","year":"2020","journal-title":"J Clin Pharm Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1270115","article-title":"Corrigendum: Glp-1ras caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101624","article-title":"Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus","volume":"51","author":"Cohen","year":"2025","journal-title":"Diabetes Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-0720","article-title":"Effects of lixisenatide versus liraglutide (short- and long-acting glp-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes","volume":"43","author":"Quast","year":"2020","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.5114\/ait\/208895","article-title":"New therapeutic agents for type 2 diabetes: anaesthetic considerations. a narrative review","volume":"57","author":"Doroba","year":"2025","journal-title":"Anaesthesiology Intensive Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00786-1","article-title":"A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation","volume":"11","author":"Thangavelu","year":"2020","journal-title":"Diabetes Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14134619","article-title":"Efficacy and safety of glp-1 receptor agonists and sglt-2 inhibitors in the treatment of diabetes mellitus and obesity in liver transplant recipients: a systematic review","volume":"14","author":"Costa","year":"2025","journal-title":"J Clin Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2024.11.016","article-title":"Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in lung transplant recipients: a single center report","volume":"57","author":"Fishman","year":"2025","journal-title":"Transplant Proc"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0241","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"B54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12933-025-02649-0","article-title":"Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients","volume":"24","author":"Lin","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40200-025-01801-7","article-title":"Glp-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events","volume":"25","author":"Aliyeva","year":"2026","journal-title":"J Diabetes Metab Disord"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the step 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15872","article-title":"Adherence to glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes mellitus: a nationwide registry study","volume":"26","author":"Lassen","year":"2024"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4216351\/v1","article-title":"Effects and safety of dulaglutide treatment on glucocorticoid-induced hyperglycemia in patients treated with chop therapy","author":"Suyama","year":"2024"}],"container-title":["Frontiers in Clinical Diabetes and Healthcare"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1772391\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:27:17Z","timestamp":1775795237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcdhc.2026.1772391\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":58,"alternative-id":["10.3389\/fcdhc.2026.1772391"],"URL":"https:\/\/doi.org\/10.3389\/fcdhc.2026.1772391","relation":{},"ISSN":["2673-6616"],"issn-type":[{"value":"2673-6616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"article-number":"1772391"}}